The Globe and Mail reports in its Thursday, July 6, edition that ATB Capital Markets analyst Frederico Gomes has resumed coverage on Ascend Wellness Holdings with an "outperform" recommendation and $4 (U.S.) unit target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the units at $3.83 (U.S.). Mr. Gomes says in a note: "We believe Ascend will be one of the few MSOs with double-digit sales growth in 2023 due to its outsized relative exposure to Maryland, which will launch its adult-use sales program on July 1, 2023. Additionally, Ascend's outlet model (which has now been applied to five of the company's retail locations) is a key differentiator, and it supports the company's higher-than-average sales per store. We believe the focus on high-volume locations within the outlet model will be a meaningful driver of long-term revenue growth and margin expansion." The Globe reported on Jan. 7 that BTIG analyst Jonathan DeCourcey rated Ascend Wellness "buy" with a $4 unit target. In the item Mr. DeCourcey said Ascend was "one of the cheapest stocks in the space." The units could then be had for just under $1.20 (U.S.).